Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis

Arthritis and Rheumatology

Volumn 67, Issue 8, 2015, Pages 2205-2212

  Hoffmann Vold, Anna Maria ^a   Aaløkken, Trond M ^a   Lund, May Brit ^a   Garen, Torhild ^a   Midtvedt, Øyvind ^a   Brunborg, Cathrine ^a   Gran, Jan Tore ^a   Molberg, Øyvind ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON MONOXIDE; CENTROMERE ANTIBODY;

ADULT; ARTICLE; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; LUNG FIBROSIS; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RISK FACTOR; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; COHORT ANALYSIS; COMPLICATION; COMPUTER ASSISTED TOMOGRAPHY; LUNG; LUNG DIFFUSION CAPACITY; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; PULMONARY FIBROSIS; RADIOGRAPHY; VITAL CAPACITY;

ADULT; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DIFFUSING CAPACITY; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC; TOMOGRAPHY, X-RAY COMPUTED; VITAL CAPACITY;

EID: 84938152992     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39166     Document Type: Article

References (32)

1. Steen VD, Medsger TA., Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
2. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al., Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-15.
3. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al., Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007; 66: 754-63.
4. Komocsi A, Vorobcsuk A, Faludi R, Pinter T, Lenkey Z, Kolto G, et al., The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012; 51: 1027-36.
5. Hoffmann-Vold AM, Molberg O, Midtvedt O, Garen T, Gran JT., Survival and causes of death in an unselected and complete cohort of Norwegian patients with systemic sclerosis. J Rheumatol 2013; 40: 1127-33.
6. Khanna D, Seibold JR, Wells A, Distler O, Allanore Y, Denton C, et al., Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. Curr Rheumatol Rev 2010; 6: 138-44.
7. Saketkoo LA, Mittoo S, Huscher D, Khanna D, Dellaripa PF, Distler O, et al., Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. Thorax 2014; 69: 428-36.
8. Behr J, Furst DE., Pulmonary function tests. Rheumatology (Oxford) 2008; 47 Suppl 5: v65-7.
9. Steen V., Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003; 62: 97-9.
10. Morgan C, Knight C, Lunt M, Black CM, Silman AJ., Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis 2003; 62: 146-50.
11. Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE., Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602.
12. Steen VD, Medsger TA Jr., Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43: 2437-44.
13. Wells AU., High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford) 2008; 47 Suppl 5: v59-61.
14. Winklehner A, Berger N, Maurer B, Distler O, Alkadhi H, Frauenfelder T., Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis 2012; 71: 549-52.
15. Wells AU, Hansell DM, Rubens MB, King AD, Cramer D, Black CM, et al., Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum 1997; 40: 1229-36.
16. Wells AU, Margaritopoulos GA, Antoniou KM, Denton C., Interstitial lung disease in systemic sclerosis. Semin Respir Crit Care Med 2014; 35: 213-21.
17. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al., Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-54.
18. Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al., Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52: 155-60.
19. Khanna D, Tseng CH, Farmani N, Steen V, Furst DE, Clements PJ, et al., Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63: 3078-85.
20. Launay D, Remy-Jardin M, Michon-Pasturel U, Mastora I, Hachulla E, Lambert M, et al., High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheumatol 2006; 33: 1789-801.
21. Hoffmann-Vold AM, Midtvedt O, Molberg O, Garen T, Gran JT., Prevalence of systemic sclerosis in south-east Norway. Rheumatology (Oxford) 2012; 51: 1600-5.
22. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall, A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737-47.
23. Hoffmann-Vold AM, Gunnarsson R, Garen T, Midtvedt O, Molberg O., Performance of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis (SSc) in large, well-defined cohorts of SSc and mixed connective tissue disease. J Rheumatol 2015; 42: 60-3.
24. Hachulla E, Launay D., Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011; 40: 78-83.
25. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al., Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [published erratum appears in Eur Heart J 2011;32:926]. Eur Heart J 2009; 30: 2493-537.
26. Hansell DM, Bankier AA, MacMahon H, McLoud TC, Muller NL, Remy J., Fleischner Society: glossary of terms for thoracic imaging. Radiology 2008; 246: 697-722.
27. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC., Lung volumes and forced ventilatory flows: report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal: official statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
28. Schwaiger JP, Khanna D, Gerry Coghlan J., Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. Eur Respir Rev 2013; 22: 515-25.
29. Khanna D, Tan M, Furst DE, Hill NS, McLaughlin VV, Silver RM, et al., on behalf of the QuERI-SSc Investigators. Recognition of pulmonary hypertension in the rheumatology community: lessons from a quality enhancement research initiative. Clin Exp Rheumatol 2014; 32 Suppl 86: 21-7.
30. Hsu VM, Chung L, Hummers LK, Wigley F, Simms R, Bolster M, et al., Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthritis Rheum 2014; 44: 55-62.
31. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al., Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the Scleroderma Lung Study. Chest 2009; 136: 1333-40.
32. Kim HJ, Brown MS, Elashoff R, Li G, Gjertson DW, Lynch DA, et al., Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol 2011; 21: 2455-65.